Pharmaceutical companies’ strategies for reaching the poor are maturing. But expansion is gradual.

Pharmaceutical companies are getting more sophisticated in the way they get their products to poor people and are addressing global health priorities. However, good practice is limited to a narrow range of products and countries. Opportunities to expand such targeting of efforts are yet to be realised.
Continue reading

Strategie van farmaceutische bedrijven om de armen te bereiken wordt volwassener. Maar de uitbreiding gaat stapsgewijs.

De manier waarop farmaceutische bedrijven medicijnen beschikbaar maken voor mensen in arme landen en wereldwijde gezondheidsprioriteiten aanpakken wordt steeds geavanceerder. De schaal waarop dit gebeurt beperkt zich echter nog tot een relatief klein aantal producten en landen.
Continue reading

Access to Medicine Index 2016: Pharmaunternehmen verbessern ihre Strategien, um Arme zu erreichen – doch der Ausbau ist schleichend

Pharmazeutische Unternehmen werden immer besser darin, ihre Produkte armen Menschen zur Verfügung zu stellen und globale Gesundheitsprobleme anzugehen. Trotzdem beschränken sich die bewährten Verfahren auf wenige Produkte und Länder.
Continue reading

Les stratégies des laboratoires pharmaceutiques pour atteindre les populations pauvres sont en voie de maturation. Cependant, leur application ne s’étend que graduellement.

Pour mettre leurs produits à la portée des populations pauvres, les laboratoires pharmaceutiques adoptent des stratégies plus complexes, qui répondent notamment aux priorités en matière de santé mondiale. Cependant, les bonnes pratiques se limitent à un nombre restreint de produits et de pays. Il reste encore à créer les opportunités qui permettront leur élargissement.
Continue reading

Access to Medicine Foundation announces 2016 Access to Medicine Index (Japanese News Release)

The Access to Medicine Foundation has announced today the publication of the 2016 Access to Medicine Index. GSK leads the Index for the fifth time and of the Japanese companies participating in the Index, Eisai ranked 11th while Takeda rose significantly, up five positions to rank 15th.
Continue reading

Greater emphasis on how pharmaceutical companies perform in access to medicine: methodology for the 2016 Access to Medicine Index

The Access to Medicine Index ranks the world’s leading pharmaceutical companies on their efforts to improve access to life-saving drugs, vaccines, diagnostic tests and other health technologies in developing countries.
Continue reading

Pharmaceutical industry doing more to improve access to medicine in developing countries; performance on some aspects lags

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday.
Continue reading

Sign up to receive updates about our work.